Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a prescription "Helicobacter pylori kit" (co-packaging) typically containing a combination of proton pump inhibitor (Esomeprazole), antibiotics (Amoxicillin and Clarithromycin), and occasionally Bismuth salts depending on the regional formulation. Its purpose is the eradication of *H. pylori* infection.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcers or chronic gastritis to reduce the risk of ulcer recurrence.
## Adult Dosing
* **Esomeprazole:** 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Duration:** Typically 10 to 14 days based on local resistance patterns and regional clinical guidelines.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for routine *H. pylori* eradication in children. Use is generally off-label and requires specialist infectious disease or gastroenterology consultation. Dose titration must be based on weight and local institutional protocols.
## Dose Adjustments
* **Renal Impairment:** No adjustment required for Esomeprazole. Amoxicillin/Clarithromycin require dose reduction in severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Reduce Esomeprazole dose (max 20 mg/day) in severe hepatic impairment. Clarithromycin is primarily metabolized by the liver; use with caution.
## Contraindications
* Known hypersensitivity to Esomeprazole, other proton pump inhibitors (PPIs), Amoxicillin (penicillins), or Clarithromycin (macrolides).
* Concurrent use of pimozide, ergot alkaloids, or astemizole (due to potential for fatal arrhythmias with clarithromycin).
* History of cholestatic jaundice or hepatic dysfunction associated with prior Clarithromycin use.
## Adverse Effects
* **GI:** Diarrhea (frequent), nausea, abdominal pain, dyspepsia.
* **Systemic:** Headache, altered taste (metallic taste).
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe allergic reactions (anaphylaxis), QT prolongation (Clarithromycin), and interstitial nephritis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent CYP3A4 inhibitor and may significantly increase plasma concentrations of drugs like warfarin, statins (e.g., simvastatin/lovastatin), and midazolam.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **pH-dependent drugs:** PPIs reduce the absorption of drugs requiring acidic environments (e.g., ketoconazole, atazanavir).
## Monitoring
* Baseline: Hepatic and renal function tests.
* During Therapy: Monitor for signs of *C. difficile* (persistent watery diarrhea), skin rash (Amoxicillin hypersensitivity), and cardiac rhythm (if using other QT-prolonging agents).
* Follow-up: Urea breath test or stool antigen test at least 4 weeks after completion of therapy to confirm eradication.
## Clinical Pearls
* **Adherence:** High compliance is essential; reinforce that patients must finish the full 10–14 day course to prevent antibiotic resistance.
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal.
* **Resistance:** Due to rising clarithromycin resistance, local antibiograms should be consulted to determine if this regimen is appropriate in the specific geographic region.
* **Bismuth:** If the specific kit includes bismuth subcitrate, inform the patient that it may cause harmless blackening of the stool or tongue.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by region and institution. Always verify dosages, contraindications, and drug interactions against the most current product labeling and your local institutional prescribing guidelines before administration.
